drugset / Trial / NCT06770933
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
Phase 2
Recruiting
100 enrolled
Vantage Biosciences Ltd
Vantage Biosciences Australia Pty Ltd · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.
Timeline
- Start
- 2025-02-11
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VX-01 | Unknown | 150 mg | Oral |